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Abstract
Introduction: a-Tocopheryloxyacetic acid (a-TEA) is a novel ether derivative of a-tocopherol that has generated
interest as a chemotherapeutic agent because of its selective toxicity toward tumor cells and its ability to suppress
tumor growth in various rodent and human xenograft models. We previously reported that oral a-TEA inhibited
the growth of both a transplanted (4T1) and a spontaneous MMTV-PyMT mouse model of breast cancer.
Methods: Because little is known about the possible immunological mechanisms underlying the in vivo a-TEA
effects, we evaluated the impact of a-TEA therapy on the immune response by characterizing immune cell
populations infiltrating the tumor site.
Results: a-TEA treatment resulted in higher frequencies of activated T cells in the tumor microenvironment and
twofold and sixfold higher ratios of CD4
+ and CD8
+ T cells to regulatory T cells, respectively. This finding was
correlated with an increased ability of tumor-draining lymph node cells and splenocytes from a-TEA-treated mice
to secrete interferon (IFN)-g in response to CD3 or to mediate a cytolytic response in a tumor-specific fashion,
respectively. That the a-TEA-mediated antitumor effect had a T cell-dependent component was demonstrated by
the partial abrogation of tumor suppression when CD4
+ and CD8
+ T cells were depleted. We also determined the
intratumoral cytokine and chemokine profile and found that a-TEA treatment increased intratumoral IFN-g levels
but decreased interleukin (IL)-4 levels, suggesting a shift toward a TH1 response. In addition, a-TEA induced higher
levels of the inflammatory cytokine IL-6 and the chemokine CCL5.
Conclusions: Taken together, these data suggest that a-TEA treatment, in addition to its direct cytotoxic effects,
enhanced the anti-tumor immune response. This study provides a better understanding of the mechanisms of
action of a-TEA and its effect on the immune system and may prove useful in designing immune-stimulating
strategies to boost the antitumor effects of a-TEA in breast cancer patients.
Introduction
Over the past several years, vitamin E a-tocopherol
(a-TOH) analogs (VEA) have been evaluated for their
antitumor activities. Of these analogs, a-tocopheryl suc-
cinate (a-TOS) and a-tocopheryloxyacetic acid (a-TEA)
have been the most studied [1-9]. Both analogs have
generated great interest as potential chemotherapeutic
agents because they exhibit selective toxicity toward
tumor cells [7,10-13] and suppress tumor growth in var-
ious rodent and human xenograft tumor models
[5,7,9,11,14-18]. a-TEA structurally shares the phytyl
tail and the chroman head with a-TOH, but differs
from a-TOH in that the hydroxyl group at the number
6 carbon of the phenolic ring of the chroman head is
replaced by an acetic acid residue that is attached by a
nonhydrolyzable ether bond [7] which makes oral
administration of a-TEA possible. In this respect, we
reported that, when it is supplied to mice in their diet,
a-TEA significantly inhibited the growth of a trans-
planted, highly metastatic breast cancer, dramatically
reduced the incidence of lung metastases [9] and was
able to delay the onset of and suppress tumor growth in
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model of breast cancer [18].
Recent data demonstrating that certain classes of che-
motherapeutic drugs cause immunogenic tumor cell
death, which leads to enhancement of antigen cross-
presentation and stimulation of the antitumor immune
response, have galvanized interest in chemotherapeutic
agents as immune modulators [19-23]. It is well docu-
mented that one mechanism of VEA-mediated tumor
cell death involves proapoptotic signaling and downre-
gulation of survival pathways [2,24]. In addition, we
have demonstrated by in situ analysis of tumor tissues
in the MMTV-PyMT mouse spontaneous breast cancer
model that apoptotic cell death is an important mechan-
ism of a-TEA-mediated tumor suppression [18]. How-
ever, the majority of studies that have examined the
mechanism of a-TOS- or a-TEA-induced anticancer
activity have only focused on the proapoptotic nature of
these analogs [3,24,25]. Therefore, little is known about
the possible immunological mechanisms that underlie
the in vivo antitumor effects of these VEAs. In this
regard, we have shown that these VEAs synergize with
ex vivo generated dendritic cells (DCs) to inhibit the
growth of established primary mammary tumors and
suppress the formation of spontaneously arising metas-
tases [17,26,27]. This finding led us to hypothesize that
the in vivo antitumor effects of a- T E Am a yh a v ea n
immune component. In this report, we demonstrate that
a-TEA increased the frequencies of activated CD4
+ and
CD8
+ T cells in the tumor microenvironment, induced a
tumor-specific cytotoxic lymphocyte response and
resulted in higher CD4
+-to-Treg and CD8
+-to-Treg
ratios, as well as that the a-TEA-mediated antitumor
effect was dependent on the T cell response. a-TEA
treatment also modulated the intratumoral cytokine and
chemokine milieus. Most notably, a-TEA increased
intratumoral interferon (IFN)-g levels but decreased
interleukin (IL)-4 levels, suggesting a shift toward a T
cell-mediated T helper type 1 (TH1) response. This
study demonstrates for the first time the immunostimu-
latory activities of a-TEA. This knowledge that a-TEA
can stimulate the immune system while directly killing
tumor cells may prove useful in designing combination
immunotherapy strategies to boost the antitumor effects
of a-TEA in breast cancer patients.
Materials and methods
Preparation of a-tocopheryloxyacetic acid
a-TEA, 2,5,7,8-tetramethyl-(2R-(4R,8R,12-trimethyltride-
cyl) chroman-6-yloxy) acetic acid, was synthesized at
The Arizona Cancer Center Synthetic Shared Resource
at The University of Arizona (Tucson, AZ) using modi-
fied previously described methods [7,28]. To a suspen-
sion of NaH (4.3 g, 181 mM) in dry tetrahydrofuran
(THF, 400 mL) under argon at 0°C was added a solution
of (R,R,R)-a-tocopherol (59.9 g, 139 mM) in dry THF
(200 mL). The mixture was stirred at 0°C for 30 min-
utes, and ethyl bromoacetate (27.8 g, 167 mM, 18.5 mL)
was added via syringe. The reaction mixture was stirred
for 3.5 hours at 0°C and for 24 hours at room tempera-
ture (RT). The reaction mixture was poured slowly into
ice water (500 mL) and extracted with ether (200 mL ×
4). The ether extracts were combined, washed with
brine, dried over MgSO4, filtered and evaporated under
reduced pressure to produce the ethyl ester of a-TEA
(71.0 g, 100%) as viscous oil. The ester was dissolved in
T H F( 7 0 0m L ) ,1 0 %a q u e o u sK O Hs o l u t i o n( 2 6 0m L ,
419 mmol) was added and the mixture was stirred at
room temperature for 6 hours. The reaction was
quenched with water (300 mL) and the pH of the solu-
tion adjusted to pH 3 using 1N HCl. The product was
extracted with ether (200 mL × 4). The combined ether
extracts were washed with brine, dried over MgSO4, fil-
tered, and evaporated to give impure a-TEA as viscous
yellow oil. Crystallization of the oil from pentane at -20°
C produced pure a-TEA (55.0 g, 113 mM, 82%) as a
white waxy solid, mp 54°C [7] (mp 54°C to 55°C), [a]D
23
+0.8 (c 1, CHCl3). Purity and identity were confirmed by
high-performance liquid chromatography and nuclear
magnetic resonance analysis.
1HN M R( 6 0 0M H z ,
CDCl3) δ 0.85 (12, m), 1.02 to 1.14 (7, m), 1.16 to 1.43
(14, m), 1.49 to 1.55 (3, m), 1.74 to 1.82 (2, m), 2.07 (3,
s ) ,2 . 1 3( 3 ,s ) ,2 . 1 7( 3 ,s ) ,2 . 5 6( 2 ,m ) ,4 . 3 6( 2 ,m ) ;
13C
NMR (150 MHz, CDCl3) δ 11.7, 11.8, 12.7, 19.6, 19.7,
20.6, 20.9, 22.6, 22.7, 23.8, 24.4, 24.7, 27.9, 31.1, 32.6,
32.7, 37.2, 37.3, 37.4, 39.3, 40.0, 69.1, 74.9, 117.7, 123.2,
125.4, 127.3, 147.0, 148.5, 173.3. HRMS (LCQ/FTICR,
Thermo Fisher Scientific, Waltham, MA, USA) calcu-
lated for C31H51O4 487.3793 [M-H]
-, observed 487.3794.
Tumor cells and cell culture
The 4T1 tumor cell line is a variant of 410.4, a tumor sub-
line that was isolated from a spontaneous mammary
tumor in a BALB/cfC3H mouse. The 4T1 tumor is poorly
immunogenic and highly metastatic and spontaneously
metastasizes to the liver, lungs, bone marrow and brain
[29-31]. The Renca cell line was derived from a sponta-
neous renal cortical adenocarcinoma in BALB/c mice [32].
The tumor cells (4T1 and Renca) were maintained in Dul-
becco’sm o d i f i e dE a g l e ’s medium (DMEM; Lonza, Walk-
ersville, MD, USA), containing 100 U/mL penicillin, 100
mg/mL streptomycin (HyClone Laboratories, Logan, UT,
USA), 0.025 mg/mL amphotericin B (HyClone Labora-
tories) and 10% fetal bovine serum (FBS; Lonza).
Animal studies
Six- to eight-week-old female BALB/c mice were pur-
chased from Harlan Laboratories (Indianapolis, IN,
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Chiles Research Institute in accordance with the Princi-
ples of Animal Care (National Institutes of Health publi-
cation 85-23). All studies were reviewed and approved
by the institutional animal care and use committee of
the Earle A. Chiles Research Institute. For the transplan-
table tumor model studies, 5 × 10
4 viable 4T1 breast
cancer cells were injected subcutaneously into the right
mammary fat pad of mice. The mice received a nutri-
ent-matched control diet (Harlan Teklad, Madison, WI,
USA) until tumor establishment (day 10 post-tumor
implantation, average tumor size of ~15 mm
2) and were
then switched to mouse chow containing a-TEA.
a-TEA was incorporated into the AIN93G diet by Har-
lan Teklad at a concentration of 3 g a-TEA/kg chow
(0.3%), resulting in a dose of ~6 mg of a-TEA per day
per mouse (equivalent to ~300 mg of a-TEA/1 kg body
wt). For T cell depletions, mice were injected intraperi-
toneally with 200 μg of CD4-specific (GK1.5) and CD8-
specific (2.43) antibodies (BioXCell, West Lebanon, NH,
USA) on day 9 post-tumor injection (1 day before initia-
tion of a-TEA therapy) and weekly thereafter. Control
animals received rat immunoglobulin G 2b (IgG2b)
(LTF-2) isotype control antibody (BioXCell). Depletion
of T cells was monitored in peripheral blood by flow
cytometry, and the frequency of CD4
+ and CD8
+ T cells
was less than 0.5%. Tumor growth was monitored by
measuring the tumor length (L) and width (W) using
calipers and calculating the tumor area as A = (L × W).
Isolation of lymph node, splenic and tumor infiltrating
immune cells
Tumor-draining inguinal lymph nodes were resected
and pushed through a 70-μm nylon sieve (BD Bios-
ciences Discovery Labware, Two Oaks, CA, USA) to
produce a single cell suspension. The cells were then
washed (300 × g for 7 minutes) and filtered through a
40-μm nylon sieve (BD Biosciences). Spleens were
resected and pushed through a 70-μm nylon sieve to
produce a single cell suspension. After red blood cell
lysis, the cells were washed (300 × g for 7 minutes) and
filtered through a 40-μm nylon sieve. To isolate tumor-
infiltrating immune cells (TICs), tumors were resected
and minced using a scalpel blade in a triple enzyme
digestion mix containing 10 mg/mL collagenase type IV
(Worthington Biochemical Corp., Lakewood, NJ, USA),
1 mg/mL hyaluronidase (Sigma - A l d r i c h ,S t .L o u i s ,M O ,
USA), 200 μg/mL DNAse I (Roche Applied Sciences,
Indianapolis, IN, USA) in Hanks’ Balanced Salt Solution
(Lonza). The tumors were then incubated with agitation
(37°C for 45 minutes). After the addition of 10 mM
ethylenediaminetetraacetic acid, the digestion product
was incubated for another 15 minutes. Subsequently, the
digested tissue was pushed sequentially through 70-μm
and 40-μm nylon sieves, washed (300 × g for 7 minutes),
overlaid on Ficoll (FicoLite-LM; Atlanta Biologicals,
Lawrenceville, GA, USA) and centrifuged (1,500 × g for
25 minutes without brake). The interface was collected
and washed twice (300 × g for 7 minutes).
In vitro stimulation of lymph node cells
Inguinal tumor-draining lymph nodes (TDLN) were
resected, and a single cell suspension was prepared as
described above. Cells were pooled from three mice per
treatment group, and 1 × 10
6 TDLN cells per well were
incubated for 48 hours in a 24-well tissue culture plate in
1 mL of Roswell Park Memorial Institute 1640 (RPMI
1640) medium containing 100 U/mL penicillin, 100 mg/
mL streptomycin (HyClone Laboratories), 0.025 mg/mL
amphotericin B (HyClone Laboratories), 70 μM b-2-
mercaptoethanol (Sigma-Aldrich), 2 mM L-glutamine
(Lonza), 1 mM sodium pyruvate (Lonza), 1× nonessential
amino acids (Lonza), 10 mM HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid; Lonza) and 10% FBS
(Lonza). For CD3 stimulation, wells were coated with
5 μg/mL anti-CD3 antibody (BD Pharmingen, San Jose,
C A ,U S A )f o r2 4h o u r sa t4 ° Ca n dw a s h e dw i t hp h o s -
phate-buffered saline before addition of lymph node cells.
Supernatants were collected after 48 hours and stored
frozen (-80°C) until analysis. IFN-g levels were deter-
mined by enzyme-linked immunosorbent assay (ELISA;
eBioscience, San Diego, CA, USA, and BD Biosciences)
according to the manufacturers’ instructions.
Cytotoxicity assay
Splenocytes were isolated as described above and pooled
from three mice per treatment group (2 × 10
6 cells/well
in 2 mL RPMI 1640) and cultured in 24-well tissue cul-
ture plates in the presence of 100 μg/mL 4T1 tumor cell
freeze-thaw lysate and 10 U/mL IL-2 for 6 days. A stan-
dard
51Cr release cytotoxicity assay was performed [33]
using Renca cells as irrelevant targets. Briefly, cultured
splenocytes (effectors) were diluted to achieve a range of
effector-to-target ratios and added in triplicate to
51Cr-labeled target cells (4T1 or Renca) in U-bottomed
96-well plates. After incubation for 6 hours (37°C, 5%
CO2), 25 μL of supernatant was added to 150 μLo f
Optiphase Supermax scintillation fluid (Perkin-Elmer,
Waltham, MA, USA) and mixed by shaking for 10 min-
utes. The released
51Cr (experimental) was quantified
using a Trilux 1450 MicroBeta Liquid Scintillation
Counter (Perkin-Elmer). The total
51Cr amount incorpo-
rated into tumor cells was determined by lysing
51Cr-
labeled cells with Triton X-100 (Sigma-Aldrich). Sponta-
neous
51Cr release was measured by using supernatant
from
51Cr-labeled cells that were incubated with media
alone. The percentage of specific tumor cell lysis was
calculated using the following formula: % cytotoxicity =
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neous)] × 100. Spontaneous release did not exceed 15%
and 25% for 4T1 and Renca cells, respectively.
Flow cytometric analysis
Lymph node cells and TICs were stained with fluoro-
phore-conjugated antibodies and analyzed by five- or six-
color flow cytometry on an LSR-II flow cytometer (BD
Biosciences). Antibodies used for five-color flow cytome-
t r yw e r eC D 3 - F I T C( e B i o s c i e n c e ) ,C D 4 - A P C - H 7( B D
Pharmingen), CD8-Pacific Orange (Caltag, Carlsbad, CA,
USA), CD25-PE (Caltag) and Foxp3-APC (eBioscience).
For intracellular Foxp3 staining, cells were permeabilized
and fixed using a fixation and permeabilization kit
(eBioscience). Antibodies used for six-color flow cytome-
try were CD3-PerCP-Cy5.5 (eBioscience), CD4-APC-H7
( B DP h a r m i n g e n ) ,C D 8 - P a c i f ic Orange (Caltag), CD25-
APC (eBioscience), CD44-FITC (eBioscience) and
CD62L-PE-TR (Caltag). Cell viability was assessed using
the LIVE/DEAD Fixable Violet stain (Invitrogen, Carls-
bad, CA, USA). Data were acquired using DIVA software
(BD Biosciences) and analyzed using either FlowJo v8.8.4
(Tree Star Inc., Ashland, OR, USA) or Winlist™ 7.0 soft-
ware (Verity House Software, Topsham, ME, USA),
including combination function (FCOM) analysis.
Multiplex analysis
To identify the soluble factors in the tumor microenvir-
onment, tumors were resected and 100 mg of tumor tis-
sue was minced using scissors in 500-μL Bio-Plex tissue
lysis buffer (Bio-Rad, Hercules, CA, USA) containing
Complete Lysis-M protease inhibitor cocktail (Roche
Applied Sciences). Subsequently, the tumor tissue was
further homogenized using a rotor stator homogenizer
(PRO Scientific Inc., Oxford, CT, USA). The lysate was
clarified (10,000 × g for 30 minutes at 4°C), and the
supernatant was stored at -80°C until analysis. The sam-
ples were thawed on ice, and protein content was deter-
mined by bicinchoninic acid protein assay (Thermo
Scientific, Rockford, IL, USA). Cytokines and chemo-
kines were assayed using multiplex luminescent beads
(Bio-Plex Pro Cytokine custom assay; Bio-Rad) accord-
ing to the manufacturer’s instructions and analyzed
using a Bio-Plex Analyzer (Bio-Rad). Fluorescence inten-
sity was transformed into cytokine concentrations using
the Bio-Plex manager 5.0 software (Bio-Rad) and nor-
malized to protein content of the sample. The following
cytokines and chemokines were evaluated: IL-1b,I L - 2 ,
IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, granulo-
cyte macrophage colony-stimulating factor (GM-CSF),
IFN-g, chemokine C-C motif ligand 2 (CCL2), chemo-
kine C-C motif ligand 3 (CCL3), chemokine C-C motif
ligand 4 (CCL4), chemokine C-C motif ligand 5 (CCL5)
and tumor necrosis factor-a.
Statistical analysis
The statistical significance of differences among data
sets of treatment groups was assessed by using Student’s
t-test for pairwise comparisons or for comparisons of
multiple groups by one-way analysis of variance
(ANOVA) with Tukey’s Honestly Significant Difference
test to adjust for multiple comparisons. To compare
tumor growth rates, growth curves were transformed to
linearity and linear regression analysis was used to
determine slopes that were then compared by t-test.
Survival curves were estimated using the method of
Kaplan and Meier, and log-rank tests were performed to
assess differences in the hazard rates. All analyses were
performed using Prism software (GraphPad, San Diego,
CA, USA). P values ≤0.05 were considered indicative of
significant differences between data sets.
Results
Oral a-TEA therapy inhibits the growth of established
breast tumors and prolongs survival
We and others have previously demonstrated that
a-TEA is effective at inhibiting the tumor growth of
various rodent and human xenograft tumor models
[5,7,9,11,14-18]. Our research has focused on the effects
of a-TEA on breast cancer using the transplantable 4T1
murine breast cancer tumor model. Using a stringent
experimental design of treating tumors that had been
established for 10 days and were clearly palpable (~15
mm
2), we showed that a-TEA (300 mg/kg body wt) was
able to significantly suppress tumor growth (Figures 1A
and 1B). This reduction in tumor size became apparent
after ~8 days of a-TEA treatment (day 18 post-tumor
cell injection) (Figure 1B) and resulted in a 1.6-fold
reduction in average tumor area compared with mice on
a control diet (P = 0.0006). On day 26 post-tumor injec-
tion, immediately before untreated animals started to
become moribund (that is, when the tumor area reached
≥150 mm
2 or the mice died due to metastatic burden),
a-TEA treatment resulted in a 2.1-fold reduction in
average tumor size compared with untreated mice (P <
0.0001). Furthermore, a-TEA significantly prolonged the
median survival by 9 days (Figure 1C) compared with
the control diet group.
a-TEA increases the frequency of activated T cells and
promotes a less immune-suppressive environment in
tumors
Although chemotherapy is commonly thought of as
immunosuppressive, recently it has become apparent that
certain classes of chemotherapeutic drugs cause immuno-
genic tumor cell death and may act as immune modula-
tors [19-23]. Our own studies on the tumor-selective
VEAs a-TOS and a-TEA have shown that when they are
administered in combination with ex vivo generated DCs
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synergize with DCs to inhibit tumor growth [17,26,27].
This finding led us to hypothesize that the antitumor
effect of a-TEA may have an immune component. There-
fore, we examined the frequency and activation status of T
cells infiltrating the tumor site in mice with established
4T1 tumors (Figures 2A and 2B). We characterized the
immune cell composition at day 18 post-tumor implanta-
tion when a-TEA tumor suppression first became appar-
ent (Figure 1B). In addition, we analyzed the activation
status of T cells immediately before mice on the control
diet became moribund because of tumor burden (day 26
post-tumor injection). Activated T cells were identified by
polychromatic flow cytometry as CD4
+CD44
+CD62L
- or
CD8
+CD44
+CD62L
- cells after gating on live, CD3-expres-
sing cells (Figure 2A). Phenotypic characterization of TICs
revealed that a-TEA caused a significant increase (P =
0.0481) in the frequency of activated CD4
+ T cells in the
tumor microenvironment on day 18 post-tumor injection
(Figure 2B). The frequency of activated CD4
+ Tc e l l s
trended higher on day 26 post-tumor injection. In addi-
tion, a-TEA caused a moderate increase of the average
frequency of activated tumor-infiltrating CD8
+ T cells on
day 18, which reached statistical significance (P = 0.041)
on day 26.
The increase in the frequency of activated T cells was
associated with a reduction in the frequency of regula-
tory T cells (Treg). On day 18, when the tumor growth
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Figure 1 Oral a-tocopheryloxyacetic acid (a-TEA) decreases breast tumor growth and prolongs survival. BALB/c mice with established
4T1 mammary tumors (day 10, ~15 mm
2) received oral a-TEA in their diet (~6 mg/day, equivalent to 300 mg/kg body wt) or a nutrient-
matched control diet. (A) Individual tumor areas. (B) Mean tumor areas ± SEM (n = 10 mice per group). Difference in average tumor area first
reaches significance on day 18 posttumor area (dotted line). (C) Kaplan-Meier analysis of survival.
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reduction in the frequency of Treg cells in the tumor
microenvironment in comparison to mice on the control
diet (Figure 3B). On day 26, the Treg frequency in the
control mice was comparable to that of a-TEA-treated
mice.
When we evaluated the ratio of effector T cells to
Tregs (Figure 3C) in mice on the control diet, we found
that at day 18 the ratios of (1) non-Treg CD4
+ T cells
(CD4
+/FoxP3
-) to Treg cells (CD4
+/CD25
+/FoxP3
+)a n d
(2) CD8
+ T cells to Treg cells were both ~4. This was
in contrast to a-TEA-treated animals, in which these
ratios were significantly higher: ~10 (P = 0.0204) for
non-Treg CD4
+ T cells and ~30 (P = 0.0072) for CD8
+
T cells. However, at day 26, there was no difference in
the average T cell-to-Treg ratio between the two treat-
ment groups.
a-TEA treatment increases responsiveness of lymph node
cells and induces a tumor-specific immune response
Next we wanted to determine whether a-TEA treatment
influenced the responsiveness of T cells to T cell receptor
(TCR) stimulation and induced a cytotoxic T cell
response. For this purpose, tumor-draining lymph node
(TDLN) cells were isolated on day 26 post-tumor injec-
tion (after 16 days of a-TEA treatment) and stimulated
in vitro with an agonistic CD3-specific antibody to deter-
mine IFN-g secretion as a surrogate marker for T cell
activation. Our results show (Figure 4A) that the TDLN
cells isolated from the a-TEA-treated mice responded
with a threefold higher (P < 0.0001) secretion of IFN-g in
comparison to the TDLN cells from mice on the control
diet. To determine whether a-TEA also induced a
tumor-specific response, we assessed the ability of T cells
isolated from a-TEA-treated mice to cause lysis of 4T1
tumor cells. Splenocytes were restimulated in vitro with
4T1 tumor cell lysate, and tumor-specific cytolytic activ-
ity was determined by an in vitro
51Cr release assay using
4T1 and Renca cells as targets. The data in Figure 4B
show that a-TEA treatment significantly increased the
lysis of 4T1 target cells approximately fivefold compared
to no treatment. This increased cytolytic activity by sple-
nocytes from a-TEA-treated mice was specific to 4T1
tumor cells, as syngeneic, irrelevant Renca targets were
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Figure 2 Effect of a-TEA on activation status of tumor-infiltrating T cells. BALB/c mice with established 4T1 mammary tumors (day 10)
received oral a-TEA in their diet. On day 18 (D18) and day 26 (D26) posttumor injection, tumor-infiltrating immune cells (TICs) were isolated and
analyzed by polychromatic flow cytometry. (A) After applying a live cell gate, CD3
+ cells were identified by the R1 gate. Subsequently, CD8
+ and
CD4
+ T cells were delineated with the R2 and R3 gates and were then further interrogated for CD62L (R4) and CD44 (R5) expression. On the
basis of the defined positive staining regions, combination function analysis (FCOM) calculated four phenotypes (FCOM region array). Activated
T cells were identified as CD4
+CD44
+CD62L
- or CD8
+CD44
+CD62L
-. Representative FCOM arrays from CD8
+ T cells are shown. (B) TICs were
analyzed from three individual mice in each of two independent experiments. Subphenotype frequencies are based on all live tumor-infiltrating
cells.
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Page 6 of 12minimally lysed at levels similar to the cytolytic ability of
splenocytes from mice on the control diet (Figure 4B).
The antitumor effect of oral a-TEA has a T cell-dependent
component
Having shown the recruitment and activation of T cells
within tumors of a-TEA-treated mice, we wanted to
determine whether T cells play a nonredundant role in
a-TEA-mediated antitumor activity. To accomplish this,
tumor-bearing mice on the a-TEA diet were depleted of
CD4
+ and/or CD8
+ T cells and assessed for survival
(Figure 5). The median survival of immune-sufficient
mice treated with a-TEA was 42 days, in contrast to
a-TEA-treated mice lacking both CD4
+ and CD8
+ T
cells, which survived only until day 31 (P = 0.0021).
Depletion of either CD4
+ or CD8
+ T cells in a-TEA-
treated mice only moderately extended the median sur-
vival to 33 days. The data suggest that both CD4
+ and
CD8
+ T cells play nonredundant roles in a-TEA-
mediated antitumor activity.
a-TEA treatment modulates the cytokine and chemokine
milieus in the tumor microenvironment
Cytokines and chemokines play an important role in
attracting or inhibiting the infiltration of immune cells
into the tumor microenvironment and thus contribute
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Figure 3 Effect of a-TEA on regulatory T cells (Treg) in the tumor microenvironment. BALB/c mice with established 4T1 mammary tumors
(day 10) received oral a-TEA in their diet (~6 mg/day). On day 18 (D18) and day 26 (D26) post-tumor injection, TICs were isolated and analyzed
by polychromatic flow cytometry. (A) After applying a live cell gate, CD3
+ cells were delineated by the R1 gate. Subsequently, CD4
+ T cells (R2)
were further interrogated for CD25 and Foxp3 expression. Tregs were identified as CD3
+CD4
+CD25
+Foxp3
+ cells. Representative flow cytometric
analyses for D18 are shown. (B) Treg frequency. (C) Ratio of Treg to either non-Treg CD4
+ (CD4
+Foxp3
-) or CD8
+ T cells. TICs were analyzed from
three individual mice from each of two independent experiments. Subphenotype frequencies are based on all live tumor-infiltrating cells.
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Page 7 of 12to tumor growth or rejection. Therefore, we analyzed
the cytokine and chemokine profiles of the microenvir-
onment of a-TEA-treated tumors on day 21 post-tumor
injection. The results in Table 1 show that a-TEA treat-
ment induced a more proinflammatory cytokine and
chemokine environment as evidenced by 2.4-fold and
2.3-fold higher levels of IL-6 and CCL5 (RANTES),
respectively, compared to tumors from animals on the
control diet. The levels of the proinflammatory cytokine
IL-1b and the proinflammatory chemokines CCL2
(MCP-1), CCL3 (MIP1-a)a n dC C L 4( M I P 1 - a)t r e n d e d
higher in the a-TEA-treated tumors. a-TEA treatment
also resulted in a 2.2-fold increase of IFN-g level and a
2.7-fold decrease of IL-4 level, suggesting a shift toward
a TH1-mediated antitumor immune response. Interest-
ingly, a-TEA therapy also resulted in a 2.8-fold increase
of IL-5 in the tumor.
Discussion
In this study, we determined whether there is an immu-
nological basis for a-TEA-mediated antitumor activity
[7,9,18] in addition to the previously described proapop-
totic and mitochondria-destabilizing effects of the VEAs
on tumor cells [3,24,25,34]. To examine whether a-TEA
treatment modulated a T cell-mediated antitumor
immune response, we evaluated the activation status of
tumor-infiltrating T cells. While systemic antitumor
immune responses in the periphery may be informative,
it is the quality of the local immune responses at the
tumor site itself that are most important, as they deter-
mine tumor progression or rejection. The phenotypic
characterization of TICs revealed that a-TEA caused an
increase in the frequency of activated CD4
+ T cells in
the tumor microenvironment on day 18 post-tumor cell
injection. This trend was still present on day 26 post-
tumor cell injection. In addition, compared with mice
on the control diet, the frequency of activated tumor-
infiltrating CD8
+ T cells was significantly higher on day
26 in the a-TEA-treated mice. The finding of higher
proportions of T cells with an activated phenotype in
0
5000
10000
15000
20000
25000
30000
35000
Control -TEA
P<0.0001
I
F
N
-

 
(
p
g
/
m
l
)
A B
P=0.0025
P=0.0056
P=0.0206
P=0.0134
4T1 Targets
12.5:1
25:1
50:1
100:1
0
5
10
15
20
25
30
-TEA
Control
E:T
S
p
e
c
i
f
i
c
 
L
y
s
i
s
Renca Targets
12.5:1
25:1
50:1
100:1
0
5
10
15
20
25
30
-TEA
Control
E:T
Figure 4 a-TEA results in increased responsiveness to T cell receptor (TCR) stimulation and induced a tumor-specific cytotoxic
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Figure 5 a-TEA-mediated tumor suppression has a T cell-
dependent component. BALB/c mice with established 4T1
mammary tumors were depleted of T cells by intraperitoneal
injection of CD4- and/or CD8-specific antibodies and received
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Page 8 of 12the tumor suggests that a-TEA-treated mice were able
to mount a more potent antitumor immune response
that contributed to tumor suppression. This notion was
supported by the finding of threefold higher IFN-g
secretion by TDLN cells after TCR stimulation and,
more important, a fivefold increase of tumor-specific
cytolytic activity by splenocytes from a-TEA-treated ani-
mals compared with untreated animals.
To establish the involvement of the immune system in
a-TEA-mediated antitumor response, a-TEA-treated,
tumor-bearing mice were depleted of CD4
+ and CD8
+ T
cells and evaluated for survival. Our results show that the
T cell response significantly contributed to the a-TEA-
mediated prolongation of survival. The necessity of both
T cell subsets for the a-TEA antitumor effect also corre-
lated with the finding of higher frequencies of activated
CD4
+ and CD8
+ T cells in the tumor microenvironment.
It is well documented that the presence of immune
cells within tumors does not necessarily predict a favor-
able clinical outcome in cancer patients. In the majority
of cancers, tumor progression occurs even in the pre-
sence of immune cells, such as cytotoxic CD8
+ Tc e l l s
and natural killer cells [35], that are frequently asso-
ciated with cytotoxic effector functions. As Tregs consti-
tute an important component of the host cells attracted
to the tumor site, the presence of this immune suppres-
sive cell population may contribute to blunting an effec-
tive antitumor immune response and thus increase
tumor progression [36-38]. An increased frequency of
Tregs in tumors, peripheral blood and secondary lym-
phoid organs is a common occurrence in animal tumor
models [38-40] and cancer patients [37,41-43], and it is
associated with metastatic spread and poor survival
[36-38]. Determination of the frequency of Tregs at day
18, when the tumor growth curves started to diverge,
showed that a-TEA treatment resulted in a lower fre-
quency of Tregs in the tumor microenvironment. How-
ever, at day 26 post-tumor cell injection, the Treg
frequency in the untreated mice had decreased to levels
similar to the Treg frequency in the a-TEA-treated
mice. The decreased frequency of Tregs in the untreated
mice could be due to the larger tumor size in compari-
son to the a-TEA-treated animals. Furthermore, the
ratios of CD4
+ or CD8
+ T cells to Treg was twofold and
sixfold higher, respectively, in the tumors of the a-TEA-
treated animals at day 18 compared with the control
mice, and these data corroborate previous reports in
which higher CD8
+ cytotoxic T cell-to-Treg ratios in
the tumor or in lymphoid organs were associated with
improved prognosis [44-46]. These findings suggest that
a-TEA treatment created a less suppressive tumor
microenvironment that allowed effector T cells to better
eliminate tumor cells.
The notion that a-TEA treatment shaped a tumor
environment that is more favorable for immune rejec-
tion is also supported by alterations in the cytokine and
chemokine profiles in the tumor milieu of a-TEA-trea-
ted mice. In particular, a-TEA treatment resulted in a
Table 1 Cytokine and chemokine profiles in the tumor microenvironment
Cytokine/chemokine Control diet (pg/mg protein ± SEM) n a-TEA diet (pg/mg protein ± SEM) nP value
IL-1b 306.7 ± 75.2 7 463.4 ± 133.5 7 0.3177
IL-2 3.2 ± 0.3 3 6.2 ± 1.4 3 0.0989
IL-4 3.7 ± 1.6 7 0.6 ± 0.2 6 0.0044
IL-5 3.8 ± 0.4 7 10.7 ± 4.7 7 0.0379
IL-6 8.3 ± 1.8 7 19.8 ± 2.6 7 0.0016
IL-10 4.1 ± 0.6 3 9.5 ± 2.7 3 0.1143
IL-12p70 ND 7 ND 7 -
IL-13 32.9 ± 2.9 3 35.9 ± 9.9 3 0.9472
IL-17 3.2 ± 0.4 7 3.9 ± 0.4 7 0.4557
GM-CSF 22.9 ± 4.7 7 31.3 ± 4.4 7 0.1745
IFN-g 5.9 ± 0.5 3 12.9 ± 2.8 3 0.0478
CCL2 (MCP-1) 1,357.2 ± 411.3 7 2,712.8 ± 679.9 7 0.1055
CCL3 (MIP1-a) 324.7 ± 49.9 3 837.5 ± 256.2 3 0.0514
CCL4 (MIP-1b) 36.5 ± 3.7 7 61.1 ± 12.5 7 0.1440
CCL5 (RANTES) 193.6 ± 42.6 7 447.2 ± 109.5 7 0.0379
TNF-a 12.1 ± 1.3 7 13.3 ± 0.8 7 0.4415
BALB/c mice with established 4T1 mammary tumors (day 10) received oral a-TEA in their diet. On day 21 posttumor injection, tumors (n = 3 to 7 per group)
were resected and equal amounts of tissue were homogenized in tissue lysis buffer containing protease inhibitors. The lysates were clarified by centrifugation,
and cytokine and chemokine levels were determined using multiplex luminescent beads. Levels (means ± SEM) were normalized by protein content of the lysate.
a-TEA, a-tocopheryloxyacetic acid; CCL2 (MCP-1), chemokine C-C motif ligand 2 (monocyte chemotactic protein-1); CCL3 (MIP1-a), chemokine C-C motif ligand
3 (macrophage inflammatory protein 1-a); CCL4 (MIP-1b), chemokine C-C motif ligand 4 (macrophage inflammatory protein 1b); CCL5 (RANTES), chemokine C-C
motif ligand 5 (regulated upon activation, normal T-cell expressed, and secreted); GM-CSF, granulocyte macrophage colony-stimulating factor; IFN-g, interferon-g;
IL, interleukin; ND, not detectable; TNF-a, tumor necrosis factor-a.
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Page 9 of 12TH1-to-TH2 ratio (IFN-g-to-IL-4 ratio) of ~22 for the a-
TEA-treated group in comparison to ~2 for the control
group. This higher TH1-to-TH2 ratio suggests a more
robust effector T cell response, which was correlated
with higher frequencies of activated CD4
+ and CD8
+ T
cells and higher CD4
+ T cell-to-Treg and CD8
+ T cell-
to-Treg ratios in the tumors of the a-TEA-treated mice.
Although a-TEA also increased levels of IL-5, generally
considered to be a TH2-associated cytokine, IL-5 may
attract TH2-dependent antitumor effectors such as eosi-
nophils [47,48]. Furthermore, a-TEA treatment modu-
lated the tumor microenvironment in a proinflammatory
fashion, as we found significantly higher IL-6 and CCL5
levels and a trend toward higher levels of other proin-
flammatory mediators (IL-1b,C C L 2 ,C C L 3 ,C C L 4 ) .I L - 6
is a pleiotropic cytokine affecting multiple immune cell
subsets. Notably, it has been shown to antagonize the
immunosuppressive effects of TGF-b in the tumor
microenvironment [49]. Similarly to human breast cancer
[50,51], the 4T1 tumor model [52] produces large quanti-
ties of TGF-b that suppress an effective antitumor
immune response [53,54]. Previously, it was shown that
4T1 cells produce various chemokines, including CCL2,
CCL3, CCL4 and CCL5 [55], that we also detected in the
tumor microenvironment, with CCL5 levels being signifi-
cantly higher in tumors in a-TEA-treated mice. The
higher intratumoral CCL5 levels after a-TEA treatment
may contribute to the attraction of T cells to the tumor
bed, as has been shown for inflammatory sites, including
tumor sites [56,57]. However, it is not clear whether the
4T1 cells are the only source of chemokines, since
tumor-infiltrating host cells also secrete these chemo-
kines. Taken together, the cytokine and chemokine pro-
files suggest that a-TEA treatment promotes a
proinflammatory environment that is more conducive to
tumor suppression.
The ability of a-TEA to modulate the immune response
corroborates studies with other cytoreductive chemothera-
peutic agents, such as the taxanes [58] and anthracyclines
[19]. The taxane docetaxel has been demonstrated not
only to enhance the antitumor cytotoxic response but also
to modulate the tumor microenvironment by decreasing
the infiltration of myeloid-derived suppressor cells [59].
Using the EL4 tumor model, Maccubbin et al. [60] also
showed that the anthracycline doxorubicin enhanced the
cytotoxic T lymphocyte response, but it was more recently
revealed that the mechanism of this immune modulation
includes the translocation of calreticulin to the surface of
tumor cells alerting DCs to take up dying tumor cells [20],
the induction of heat shock proteins (Hsps) [61] and the
secretion of high-mobility group 1 proteins [62]. We
hypothesize that a-TEA may cause immunogenic tumor
cell death, resulting in the upregulation and/or release of
endogenous damage-associated molecular pattern
molecules, such as Hsps [62-70] and the release of putative
tumor-associated antigens that can be ingested by DCs
and efficiently cross-presented to stimulate naïve tumor-
specific T lymphocytes [71,72]. Our previous results show-
ing that a-TOS- or a-TEA-treated tumor cells upregu-
lated and translocated Hsps to the cell surface [17,27] and
that supernatant from a-TOS- or a-TEA-treated tumor
cells stimulated DC activation and maturation [17,27] lend
support to this notion. Although our findings clearly
demonstrate that a-TEA enhances the antitumor immune
response by coopting the adaptive T cell response, the
contribution of the direct killing of tumor cells by a-TEA
cannot be overlooked. We previously reported that a-TEA
induces apoptotic death of 4T1 tumor cells in vitro [9]
and confirmed that apoptosis is also involved in tumor
reduction by a-TEA in vivo [18]. Furthermore, we have
shown that a-TEA synergizes with DC vaccination to
decrease the frequency of spontaneous tumors in the
spontaneous MMTV-PyMT mouse breast cancer model
[73], demonstrating the ability of a-TEA to act as an
adjuvant.
Conclusions
a-TEA increased the frequencies of activated CD4
+ and
CD8
+ T cells, resulted in higher CD4
+-to-Treg and CD8
+-to-Treg ratios in the tumor microenvironment and
induced tumor-specific cytotoxicity. In addition, a-TEA
treatment modulated the intratumoral cytokine and che-
mokine milieus in a manner that suggests a shift toward
a T cell-mediated TH1 response. To the best of our
knowledge, this study demonstrates for the first time
that, in addition to the direct cytotoxic effect on tumor
cells, a-TEA suppresses in vivo breast tumor growth in
a T cell-dependent manner.
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